Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
From the Editor

The gift of lasting immunity

Brian F. Mandell, MD, PhD
Cleveland Clinic Journal of Medicine May 2025, 92 (5) 263-264; DOI: https://doi.org/10.3949/ccjm.92b.05025
Brian F. Mandell
Roles: Editor in Chief
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
  • Article
  • Info & Metrics
  • PDF
Loading

Embedded Image

In this issue of the Journal, Rivard1 reviews and discusses some of the current guidelines for vaccination of patients against measles. Reading through the practical US Centers for Disease Control and Prevention recommendations for prevention of measles1,2 prompted me to reflect on the degree and perhaps surprising duration of immunity acquired from natural infection and the attenuated measles vaccine. Of historical interest is a detailed description by Peter Panum3 of a measles epidemic on the Faroe Islands in 1846. A prior measles outbreak occurred on the islands in 1781. Panum estimated that 5,000 of the 6,626 inhabitants in 1846 were infected, and at least 78 died. His notable observation was that the infection rate was fairly similar across age groups, with the exception that the elderly (age > 65, those who would have been alive during the 1781 epidemic) were spared. This seminal epidemiologic observation has since been corroborated with serologic data4 and extended to include data on the lasting serologic and clinical efficacy of the live attenuated measles vaccine.5 This can be contrasted with the recommendation that adults should receive booster vaccinations for tetanus and diphtheria every decade.6

The duration of efficacy of vaccines varies significantly depending on the type of vaccine, its structure, the age at which it is given, and, likely, the pathogen it targets. Studies have shown that the measles vaccine, which is a live attenuated virus, is highly effective, with a median effectiveness of 93% after 1 dose and 97% after 2 doses.1 The second dose in the usual regimen is not a “booster,” but it provides immunity to those who do not respond to the first dose. Although not necessarily lifelong for all individuals, measles vaccine–induced immunity is quite durable. This distinguishes the measles vaccine from some others. For instance, the tetanus and pertussis vaccines (nonreplicating antigen–containing platforms) typically require booster doses every 10 years to maintain full immunity. Other nonreplicating vaccines, like the hepatitis B vaccine, provide long-term protection, often lasting decades without the need for boosters. So it is not just live vs “dead” that dictates duration of efficacy.

The measles virus, and the attenuated live virus used in the measles vaccine, are enveloped, single-stranded RNA viruses. Unlike many RNA viruses, the measles virus and attenuated live virus are extremely stable, eliminating the need for periodic vaccine modifications as required for influenza and COVID. The attenuated live virus has multiple sequence differences from the native measles virus, resulting in decreased replication in immune cells, but the full explanation for its decreased pathogenicity and lasting immunity is not known.

The durability of immunity following natural infection with measles, and of the usually self-limited but occasionally severe general immunosuppression associated with acute infection (immune amnesia), may be based in the life cycle of the infecting virus. Initial infection is mediated by uptake of the virus by several different receptors into immune cells, first in the airways, including T and B lymphocytes, dendritic cells, and activated monocytes, some of which will transport the virus to lymph nodes around the body. Humoral and cell-mediated immunity are stimulated, and the prolonged presence of virus may drive the maturation of the specific humoral response while at the same time causing suppression of both delayed hypersensitivity to recall antigens and humoral responses to preexisting nonmeasles antigens.7 This “immune amnesia” may last several years and predispose affected patients to other infections, a contributor to the morbidity of measles infection. Interestingly, the attenuated measles vaccine does not induce this immunosuppression,8 possibly due to decreased infection of immune cells compared with the natural measles virus.9

The long-lasting antimeasles immunoglobulin G antibody response is protective against reinfection, while the cell-mediated antivirus response is required to abrogate the active infection. The measles virus invades and replicates in airway columnar epithelial cells, resulting in desquamation of cells into the airway, which permits spreading of the virions and virus-infected cells through coughing and sneezing.

At present, there is no available potent antiviral treatment for measles. Given the durable efficacy of the available attenuated live measles vaccine and the lack of any nonhuman host or environmental reservoir, eradication of this disease is a potential reality.

For those interested in reading a well-referenced overview of the measles virus, I’d suggest looking at a paper by Moss and Griffin.10

  • Copyright © 2025 The Cleveland Clinic Foundation. All Rights Reserved.

References

  1. ↵
    1. Rivard KR
    . Does my patient need a measles vaccine? Cleve Clin J Med 2025; 92(5):279–282. doi:10.3949/ccjm.92a.25038
    OpenUrlFREE Full Text
  2. ↵
    1. McLean HQ,
    2. Fiebelkorn AP,
    3. Temte JL,
    4. Wallace GS
    . Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Recomm Rep 2015; 64(9):259]. MMWR Recomm Rep 2013; 62(RR–04):1–34. pmid:23760231
    OpenUrlPubMed
  3. ↵
    1. Buck C,
    2. Llopis A,
    3. Najera E,
    4. Terris M
    1. Panum PL
    . Observations made during the epidemic of measles on the Faroe Islands in the year 1846. In: Buck C, Llopis A, Najera E, Terris M, eds. The Challenge of Epidemology: Issues and Selected Readings. Washington, DC: Pan American Health Organization; 1988:37–41.
  4. ↵
    1. Bolotin S,
    2. Osman S,
    3. Hughes SL, et al
    . In elimination settings, measles antibodies wane after vaccination but not after infection: a systematic review and meta-analysis. J Infect Dis 2022; 226(7):1127–1139. doi:10.1093/infdis/jiac039
    OpenUrlCrossRefPubMed
  5. ↵
    1. Franconeri L,
    2. Antona D,
    3. Cauchemez S,
    4. Lévy-Bruhl D,
    5. Paireau J
    . Two-dose measles vaccine effectiveness remains high over time: a French observational study, 2017–2019. Vaccine 2023; 41(39):5797–5804. doi:10.1016/j.vaccine.2023.08.018
    OpenUrlCrossRefPubMed
  6. ↵
    1. Havers FP,
    2. Moro PL,
    3. Hunter P,
    4. Hariri S,
    5. Bernstein H
    . Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2019. MMWR Morb Mortal Wkly Rep 2020; 69(3):77–83. doi:10.15585/mmwr.mm6903a5
    OpenUrlCrossRefPubMed
  7. ↵
    1. Griffin DE
    . Measles virus-induced suppression of immune responses. Immunol Rev 2010; 236:176–189. doi:10.1111/j.1600-065X.2010.00925.x
    OpenUrlCrossRefPubMed
  8. ↵
    1. Mina MJ,
    2. Kula T,
    3. Leng Y, et al
    . Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science 2019; 366(6465):599–606. doi:10.1126/science.aay6485
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Condack C,
    2. Grivel JC,
    3. Devaux P,
    4. Margolis L,
    5. Cattaneo R
    . Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration. J Infect Dis 2007; 196(4):541–549. doi:10.1086/519689
    OpenUrlCrossRefPubMed
  10. ↵
    1. Moss WJ,
    2. Griffin DE
    . What’s going on with measles? J Virol 2024; 98(8):e0075824. doi:10.1128/jvi.00758-24
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 92 (5)
Cleveland Clinic Journal of Medicine
Vol. 92, Issue 5
1 May 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The gift of lasting immunity
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The gift of lasting immunity
Brian F. Mandell
Cleveland Clinic Journal of Medicine May 2025, 92 (5) 263-264; DOI: 10.3949/ccjm.92b.05025

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The gift of lasting immunity
Brian F. Mandell
Cleveland Clinic Journal of Medicine May 2025, 92 (5) 263-264; DOI: 10.3949/ccjm.92b.05025
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Psychedelics in the medical toolbox?
  • All sulfa drugs are not created equal
Show more From the Editor

Similar Articles

Subjects

  • Infectious Diseases

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire